TR200001717T2 - Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler. - Google Patents

Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler.

Info

Publication number
TR200001717T2
TR200001717T2 TR2000/01717T TR200001717T TR200001717T2 TR 200001717 T2 TR200001717 T2 TR 200001717T2 TR 2000/01717 T TR2000/01717 T TR 2000/01717T TR 200001717 T TR200001717 T TR 200001717T TR 200001717 T2 TR200001717 T2 TR 200001717T2
Authority
TR
Turkey
Prior art keywords
treatment
compositions containing
leishmaniasis
pharmaceutical compositions
solid pharmaceutical
Prior art date
Application number
TR2000/01717T
Other languages
English (en)
Inventor
Angel J�Rgen
Sarlikiotis Werner
Klenner Thomas
Hilgard Peter
Sauerbier Dieter
Milsmann Eckhard
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of TR200001717T2 publication Critical patent/TR200001717T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Söz konusu bulus leishmaniasis tedavisinde heksadesilfosfokolin (miltefosin) ihtiva eden ve agizdan alinan yeni kati farmasötik bilesimler, bahsi geçen farmasötik bilesimin imalati için bir yöntem, leishmania hastaligi tedavisinde kullanilmak üzere bahsi geçen farmasötik bilesimin agizdan uygulanmasi için bir doz plani ve son olarak da bahsi geçen kati farmasötik bilesimin bir kusma önleyici ve/veya bir ishal önleyici ile birlikte kullanilmasi ile ilgilidir.
TR2000/01717T 1998-01-22 1998-01-22 Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler. TR200001717T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
TR200001717T2 true TR200001717T2 (tr) 2000-11-21

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01717T TR200001717T2 (tr) 1998-01-22 1998-01-22 Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler.

Country Status (24)

Country Link
US (1) US6544551B1 (tr)
EP (1) EP1051159B1 (tr)
JP (1) JP2002501015A (tr)
KR (1) KR100517399B1 (tr)
CN (1) CN100413492C (tr)
AT (1) ATE215817T1 (tr)
AU (1) AU756805B2 (tr)
BR (1) BR9814772A (tr)
CA (1) CA2318260C (tr)
CZ (1) CZ299229B6 (tr)
DE (1) DE69804865T2 (tr)
DK (1) DK1051159T3 (tr)
ES (1) ES2175663T3 (tr)
HU (1) HUP0004363A3 (tr)
IL (1) IL136196A (tr)
NO (1) NO20003674D0 (tr)
NZ (1) NZ505648A (tr)
PL (1) PL189654B1 (tr)
PT (1) PT1051159E (tr)
SI (1) SI1051159T1 (tr)
SK (1) SK284839B6 (tr)
TR (1) TR200001717T2 (tr)
UA (1) UA68372C2 (tr)
WO (1) WO1999037289A1 (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
BR0215680A (pt) * 2002-04-26 2005-02-01 Rudolf Perl Composição farmacêutica oral estável
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AU2003253350B2 (en) 2002-07-30 2008-06-26 Aeterna Zentaris Gmbh Use of alkyl phosphocholines in combination with antitumor medicaments
BRPI0410805A (pt) 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
PT2642981T (pt) 2010-11-22 2017-06-16 Oblita Therapeutics Bvba Resumo
RU2678561C9 (ru) 2011-06-24 2019-03-05 ДжиАрАй Био, Инк. Предупреждение и лечение воспалительных состояний
EP2983709A1 (en) * 2013-04-08 2016-02-17 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
US20170252295A1 (en) 2014-09-17 2017-09-07 Steerlife India Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
CA3136525A1 (en) * 2019-04-12 2020-10-15 Oblita Therapeutics Bvba Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
DE69804865D1 (de) 2002-05-16
CN100413492C (zh) 2008-08-27
EP1051159B1 (en) 2002-04-10
UA68372C2 (en) 2004-08-16
AU6212198A (en) 1999-08-09
BR9814772A (pt) 2000-10-24
DE69804865T2 (de) 2002-11-07
CA2318260A1 (en) 1999-07-29
SK9862000A3 (en) 2000-11-07
NO20003674L (no) 2000-07-18
HUP0004363A3 (en) 2002-12-28
EP1051159A1 (en) 2000-11-15
SK284839B6 (sk) 2005-12-01
WO1999037289A1 (en) 1999-07-29
CZ20002596A3 (cs) 2000-10-11
US6544551B1 (en) 2003-04-08
SI1051159T1 (en) 2002-10-31
PL189654B1 (pl) 2005-09-30
AU756805B2 (en) 2003-01-23
NZ505648A (en) 2002-10-25
KR100517399B1 (ko) 2005-09-28
CN1283111A (zh) 2001-02-07
IL136196A (en) 2004-07-25
NO20003674D0 (no) 2000-07-18
ES2175663T3 (es) 2002-11-16
DK1051159T3 (da) 2002-08-05
JP2002501015A (ja) 2002-01-15
PL342838A1 (en) 2001-07-16
HUP0004363A2 (hu) 2001-04-28
CA2318260C (en) 2006-11-21
KR20010034311A (ko) 2001-04-25
PT1051159E (pt) 2002-09-30
ATE215817T1 (de) 2002-04-15
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
TR200001717T2 (tr) Leishmaniasis tedavisinde miltefosin ihtiva eden ve ağızdan alınan katı farmasötik bileşimler.
DE69940674D1 (de) Orale verabreichung von adenosin analogen
BR9914251A (pt) Formulações orais de liberação sustentada
BR9713835A (pt) Processos para fabricação de uma escova de dentes e para aplicação de uma substância as dentes, e, escova de dentes
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
TR200100172T2 (tr) Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR9810495A (pt) Composição farmacêutica
IS4553A (is) Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
SE9700885D0 (sv) New pharmaceutical formulation
MY101566A (en) Pharmaceutical compositions.
DE69828043D1 (de) Fluoridfreie zahnremineralisierung
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
ATE210448T1 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
ATE149793T1 (de) Fungizide zusammensetzungen
FI884241A (fi) Komposition avsedd att foerhindra kvicksilverfoergiftning orsakad av upploesning av kvicksilver ur amalgamplomber.
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
TR200101729T2 (tr) IL-5 engelleyici 6-azaurasil türevleri
BR9910465A (pt) Uso de um agente que mantém ou melhora a barreira de permeabilidade da gengiva
ATE218366T1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung
UA34265A (uk) Паста для лікування захворювань тканин пародонту